![]() |
市場調査レポート
商品コード
1541226
心臓再同期療法(CRT)市場レポート:タイプ、用途、エンドユーザー、地域別、2024年~2032年Cardiac Resynchronization Therapy Market Report by Type, Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, Atrioventricular Dyssynchrony), End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
心臓再同期療法(CRT)市場レポート:タイプ、用途、エンドユーザー、地域別、2024年~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2~3営業日
|
世界の心臓再同期療法(CRT)市場規模は2023年に57億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに93億米ドルに達し、2024~2032年の成長率(CAGR)は5.4%になると予測しています。心不全の有病率の上昇、政府・規制当局による支援の増加、有利な償還政策、新興国におけるヘルスケアインフラの拡充などが、市場を後押しする主な要因となっています。
心臓再同期療法(CRT)は、特定の患者の心不全症状を治療するために用いられる高度な医療処置です。この治療には、ペースメーカーに似たCRT装置として知られる、胸部に外科的に埋め込む特殊な装置の使用が含まれます。この装置は、心臓の各室に電気的インパルスを送信することによって機能し、それによって各室の収縮を調整します。この同期によって心臓の効率が向上し、心不全にしばしば伴う疲労や息切れなどの症状が緩和されます。CRTは通常、最適な内科的治療と併用して、心臓内の電気的混乱が認められる中等度から重度の心不全患者に対して考慮されます。CRTの導入は、患者のQOLと全体的な機能能力を改善することを目的とした、心不全管理への的を絞ったアプローチを意味します。
特に新興経済諸国における急速なヘルスケアインフラの開発は、CRT機器の普及拡大に重要な役割を果たしており、予測期間中の市場成長を刺激するものと思われます。各国が医療施設の近代化、医療専門家の育成、ヘルスケア・システムの強化に投資しているため、CRTのような専門的治療へのアクセスがより広まりつつあります。これに加え、患者が市場競争力のあるコストで高度な医療技術を提供する国で治療を受ける医療ツーリズムの増加も、市場成長を後押ししています。さらに、官民パートナーシップの増加により、CRTの資金調達と普及を目的とした政府と民間団体の協力関係が促進されています。また、教育キャンペーンや専門的なワークショップを通じて患者の認知度を高めることで、CRTの理解と受容が促進され、製品採用率が加速しています。さらに、製品開拓、マーケティング、流通におけるメーカー間の戦略的協力関係も市場の成長を支えています。このほか、費用対効果の高いCRTソリューションを提供する現地メーカーの出現が競合を助長し、治療をより身近なものにしているため、心臓再同期療法の市場の成長を後押ししています。
心不全の有病率の増加
世界の心不全発症率の上昇は、心臓再同期療法(CRT)市場の成長を促進する重要な要因です。心不全が、特に高齢化した人口集団や肥満や糖尿病の罹患率が上昇した地域で蔓延するにつれて、CRTのような効果的な治療に対する需要が高まっています。CRTが特定の心不全患者の症状や全体的なQOLを改善する能力は、その重要性を強調しています。また、さまざまな公衆衛生上の取り組みが心不全の早期発見と早期治療に重点を置いており、CRTの必要性がさらに高まっています。心不全という慢性疾患の有病率の増加により、治療ソリューションの継続的な進歩が必要とされており、CRTは現代の心不全管理戦略に不可欠な要素となっています。
急速な技術進歩
CRT分野における技術革新と進歩は、世界市場の成長に大きく寄与しています。主要企業による研究開発努力の増加は、CRTデバイスを継続的に改良し、その有効性、安全性、患者適合性を高めています。マルチポイントペーシングや適応アルゴリズムなどの技術革新により、より個別化された効率的な治療が可能になり、心不全患者の多様なニーズに対応しています。洗練された技術の統合により、他の医療システムや患者モニタリングツールとのシームレスな連携も容易になっています。このような技術の絶え間ない進化は、CRTの利点をより多くの患者層に広げると同時に、この治療法が心不全治療の最前線であり続けることを保証しています。
政府・規制当局の支援
政府と規制当局の支援はCRT市場の形成に重要な役割を果たします。明確な規制の道筋を示すことで、各国政府は新しく改良されたCRTデバイスの迅速な承認を促進しています。また、多くの国が研究イニシアチブに投資し、この分野の技術革新を促進するために業界各社と協力しています。さらに、政府が支援する医療プログラムや政策は、心不全の負担軽減に重点を置いており、CRTのような治療を支持しています。このように、心不全治療の強化を目的とした規制機関の連携は、成長を促進し、診療を標準化し、さまざまなヘルスケアシステムでCRTを利用できるようにする上で有益な、献身的なアプローチを示しています。
The global cardiac resynchronization therapy (CRT) market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The rising prevalence of heart failure, increase in government and regulatory support, favorable reimbursement policies, and expansion of healthcare infrastructure in emerging economies are some of the major factors propelling the market.
Cardiac resynchronization therapy (CRT) is an advanced medical procedure used to treat heart failure symptoms in certain patients. This treatment involves the use of a specialized device that is surgically implanted in the chest, known as a CRT device, which is akin to a pacemaker. The device functions by transmitting electrical impulses to the chambers of the heart, thereby coordinating their contractions. This synchronization can enhance the heart's efficiency, alleviating symptoms such as fatigue and shortness of breath that often accompany heart failure. CRT is typically considered for individuals with moderate to severe heart failure who display evidence of electrical disarray within the heart, in conjunction with optimal medical therapy. The implementation of CRT signifies a targeted approach to heart failure management, aimed at improving the quality of life and overall functional capacity of patients.
Rapid healthcare infrastructure development, particularly in emerging economies, is playing a vital role in expanding the reach of CRT devices, which will stimulate market growth during the forecast period. As nations invest in modernizing medical facilities, training healthcare professionals, and strengthening healthcare systems, access to specialized treatments like CRT is becoming more widespread. This, coupled with a rise in medical tourism, where patients seek treatment in countries offering advanced healthcare technologies at competitive costs, is fueling the market growth. Furthermore, the increasing public-private partnerships are fostering collaborations between governments and private entities to finance and promote CRT. Enhanced patient awareness through educational campaigns and professional workshops is also facilitating the understanding and acceptance of CRT, accelerating the product adoption rate. In addition, strategic collaborations between manufacturers for product development, marketing, and distribution are supporting market growth. Besides this, the emergence of local manufacturers offering cost-effective CRT solutions is fostering competition and making therapy more accessible, thus propelling the growth of the cardiac resynchronization therapy market.
Increase in Prevalence of Heart Failure
The rising incidence of heart failure globally is a key factor driving the growth of the cardiac resynchronization therapy (CRT) market. As heart failure becomes more prevalent, particularly in aging populations and areas with increased rates of obesity and diabetes, the demand for effective treatments like CRT is escalating. The ability of CRT to improve symptoms and overall quality of life in selected patients with heart failure underscores its importance. Various public health initiatives are also emphasizing early detection and treatment of heart failure, further propelling the need for CRT. The growing prevalence of this chronic condition necessitates continuous advancement in therapeutic solutions, making CRT an integral part of contemporary heart failure management strategies.
Rapid Technological Advancements
Technological innovation and advancements in the field of CRT are contributing significantly to the growth of the global market. Increased research and development (R&D) efforts by key players are continuously refining CRT devices, enhancing their efficacy, safety, and patient compatibility. Innovations like multi-point pacing and adaptive algorithms are enabling more personalized and efficient therapies, catering to the diverse needs of heart failure patients. The integration of sophisticated technologies also facilitates seamless coordination with other medical systems and patient monitoring tools. This constant evolution in technology is extending the benefits of CRT to a wider patient demographic while ensuring that the therapy remains at the forefront of heart failure treatment.
Favorable Government and Regulatory Support
Government and regulatory support play a crucial role in shaping the CRT market. By providing clear regulatory pathways, governments are facilitating faster approvals of new and improved CRT devices. Many countries are also investing in research initiatives and collaborating with industry players to foster innovation in the field. Moreover, government-backed health programs and policies are focusing on reducing the burden of heart failure and are thus endorsing treatments like CRT. This alignment of regulatory bodies with the objective of enhancing heart failure care demonstrates a committed approach, which is instrumental in fostering growth, standardizing practices, and ensuring the accessibility of CRT across various healthcare systems.
IMARC Group provides an analysis of the key trends in each segment of the global cardiac resynchronization therapy (CRT) market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and end user.
CRT-Defibrillator
CRT-Pacemaker
CRT-Defibrillator represents the most popular type
The report has provided a detailed breakup and analysis of the market based on the type. This includes CRT-Defibrillator and CRT-Pacemaker. According to the report, CRT-Defibrillator represented the largest segment.
The CRT-Defibrillator (CRT-D) offers dual functionality in treating heart failure patients. Unlike standard CRT devices, CRT-D combines the features of cardiac resynchronization with defibrillation capabilities. This integrated approach enables the device to synchronize the heart's chambers, improving its efficiency, as well as to detect and correct life-threatening arrhythmias. By delivering a shock to the heart when it detects irregular rhythms, the CRT-D acts as a safeguard, adding an extra layer of protection for patients at high risk of sudden cardiac arrest. The all-encompassing nature of CRT-D extends its applicability, offering a comprehensive solution for managing both the chronic symptoms of heart failure and acute, critical arrhythmias. Additionally, improvements in device miniaturization, battery life, and programmability have contributed to its popularity. This consolidation of functions into one device, providing multifaceted care, has made CRT-D a preferred option, thus fueling the segment growth.
Intraventricular Dyssynchrony
Interventricular (V-V) Dyssynchrony
Atrioventricular (A-V) Dyssynchrony
Intraventricular Dyssynchrony dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes intraventricular dyssynchrony, interventricular (V-V) dyssynchrony, and atrioventricular (A-V) dyssynchrony. According to the report, intraventricular dyssynchrony represented the largest segment.
Intraventricular dyssynchrony refers to the uncoordinated contraction of the heart's ventricles, leading to inefficient pumping and worsening heart failure symptoms. This specific form of dyssynchrony has been identified in a significant number of heart failure patients, making it a primary target for CRT. The use of CRT in managing intraventricular dyssynchrony is well-established, offering marked improvements in both symptoms and overall cardiac function. The precise targeting and correction of this dyssynchrony through CRT enables the heart to pump more efficiently, enhancing the patient's quality of life and reducing hospitalization rates. Research studies and clinical trials have further supported the effectiveness of CRT in this application, solidifying its position as a standard treatment. The pervasive presence of intraventricular dyssynchrony among heart failure patients and the proven success of CRT in addressing this condition are fueling the segment growth.
Hospitals
Cardiac Centers
Ambulatory Surgery Centers
Others
Hospitals hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cardiac centers, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.
Hospitals are often the primary setting for the diagnosis and treatment of heart failure, including the implantation and management of CRT devices. The complexity of CRT requires specialized equipment, skilled healthcare professionals, and coordinated post-procedure care, resources that hospitals are typically well-equipped to provide. Additionally, larger hospitals often have dedicated cardiac units with experts trained specifically in CRT, enabling comprehensive patient care from initial consultation through post-surgical monitoring. Many hospitals also engage in research and collaborate with device manufacturers, further aligning themselves with the advancements in CRT. The emphasis on integrated care pathways, coupled with the support of multi-disciplinary teams within the hospital setting, ensures that patients receive a seamless experience. This combination of resources, expertise, and patient-centric care is supporting the growth of the hospital segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region boasts a sophisticated healthcare infrastructure, emphasis on medical innovation, and robust regulatory support that have fostered a favorable environment for the adoption and advancement of CRT. North America is also home to a significant number of leading medical research institutions and device manufacturers, promoting continuous innovation in CRT technology. In addition, high awareness levels among healthcare professionals and the general population about heart failure and its treatment options contribute to the growing acceptance of CRT. Moreover, the prevalence of lifestyle-related diseases leading to heart failure is relatively high in this region, creating a substantial patient base. Favorable reimbursement policies and insurance coverage further ease the accessibility of CRT for patients. These factors, along with the increasing focus on patient-centered care, position North America as the largest regional market for cardiac resynchronization therapy (CRT).
The market is experiencing steady growth as key players are actively engaged in research and development (R&D), striving to innovate and enhance CRT technology. Collaborating with healthcare institutions, they are focused on creating devices with improved efficiency, patient compatibility, and integration with other healthcare systems. Expansion into emerging markets and strategic alliances with local distributors are also part of their growth strategies. Through acquisitions and partnerships, these industry leaders are consolidating their presence, sharing expertise, and fostering technological advancements. Investments in clinical trials to validate new applications and continued engagement with regulatory bodies for compliance ensure alignment with global healthcare needs. We also expect the market to witness new entrants, consolidation of portfolios, and a rise in strategic collaborations to drive healthy competition within the CRT domain.
Abbott Laboratories
Biotronik SE & Co. KG
Boston Scientific Corporation
LivaNova Plc
Medico S.p.A.
Medtronic Plc
Merit Medical Systems Inc.
MicroPort Scientific Corporation
In July 2023, Biotronik SE & Co. KG announced the approval of its next-generation portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy (CRT) devices by the U.S. Food and Drug Administration (FDA).
Abbott Laboratories has made recent developments in cardiac resynchronization therapy (CRT) by releasing updates to its implantable pacemakers and defibrillators, showcasing its commitment to continuously improve patient care.